Amino acid pairing peptide-based nanoparticles were recently introduced as promising carriers for hydrophobic anticancer drugs. The AC8 peptide, n-FEFQFNFK-c, is based on the amino acid pairing (AAP) design with 8 amino acids and hence the designated name AAP8. The nanoparticles (NPs) AAP8 have modified either on the C-terminal or on both terminal, by conjugation with diethylene glycol (DEG) . Here, the in vitro biocompatibilities of the NPs and their modified versions were compared and the potential of these NPs as carriers for the hydrophobic anticancer drug pirarubicin was determined as well as the peptide-drug co-assembly complexes. The toxicity of the NPs, DEGylated NPs, and blended mixtures with pirarubicin, was tested against the human adenocarcinoma lung cancer cell line, A549. The amino-end DEGylated NP, (NP-I), had superior biocompatibility over the non-modified NPs or double DEGylated NPs (NP-II). NP-I had very low hemolytic activity (1%) while NP and NP-II had marginal (8%) and acceptable (5%) hemolytic activity, respectively. All three types of NPs did not activate the complement system via the classical and alternative pathways nor did they activate the anaphylotoxin C3a. However, NP-II and its drug complex effectively activate the complement terminal attack complex. The lectin pathway was not activated by NP-I and NP-II, but was to a small extent by the non-modified NPs, with no lectin activation when complexed with drug. These results indicate NP-I is the most promising peptide for use as a drug delivery system, highlighting the importance of proper modification in peptides for drug delivery systems.
LangerRFolkmanJ. Polymers for the sustained release of proteins and other macromolecules. Nature1976; 263(5580): 797–800.
2.
LangerRHsiehDSTRhineW. Control of release kinetics of macromolecules from polymers. J Membrane Sci1980; 7(3): 333–350.
3.
GoldbergMLangerRJiaX. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed2007; 18(3): 241–268.
4.
ChielliniEChielliniEEChielliniF. Targeted administration of proteic drugs. I. Preparation of polymeric nanoparticles. J Bioact Compat Pol2001; 16(6): 441–465.
5.
FarokhzadOCKarpJMLangerR. Nanoparticle–aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv2006; 3(3): 311–324.
6.
ThatteSDatarKOttenbriteRM. Perspectives on: polymeric drugs and drug delivery systems. J Bioact Compat Polym2005; 20(6): 585–601.
7.
YihTCAl-FandiM. Engineered nanoparticles as precise drug delivery systems. J Cell Biochem2006; 97(6): 1184–1190.
8.
DobrovolskaiaMAAggarwalPHallJB. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm2008; 5(4): 487–495.
9.
DomanskiDMKlajnertBBryszewskaM. Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry2004; 63(1–2): 189–191.
10.
BermejoJFOrtegaPChoncoL. Water-soluble carbosilane dendrimers: synthesis biocompatibility and complexation with oligonucleotides; evaluation for medical applications. Chemistry2007; 13(2): 483–495.
11.
AgasheHBDuttaTGargM. Investigations on the toxicological profile of functionalized fifth-generation poly(propylene imine) dendrimer. J Pharm Pharmacol2006; 58(11): 1491–1498.
12.
DuttaTAgasheHBGargM. Poly(propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J Drug Target2007; 15(1): 89–98.
13.
MalikNWiwattanapatapeeRKlopschR. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of I-125-labelled polyamidoamine dendrimers in vivo. J Control Release2000; 65(1–2): 133–148.
14.
ShahDSSakthivelTTothI. DNA transfection and transfected cell viability using amphipathic asymmetric dendrimers. Int J Pharm2000; 208(1–2): 41–48.
15.
KimDEl-ShallHDennisD. Interaction of PLGA nanoparticles with human blood constituents. Colloids Surf B Biointerfaces2005; 40(2): 83–91.
16.
InadaYMatsuswmaAKoderaY. Review: polyethylene glycol (PEG)–protein conjugates: application to biomedical and biotechnological processes. J Bioact Compat Polym1990; 5: 343–364.
17.
LawSKAReidKBM. Complement. 2nd ed.Oxford; New York: IRL Press at Oxford University Press, 1995.
18.
LambrisJDRicklinDGeisbrechtBV. Complement evasion by human pathogens. Nat Rev Microbiol2008; 6(2): 132–142.
KrarupAThielSHansenA. l-ficolin is a pattern recognition molecule specific for acetyl groups. J Biol Chem2004; 279(46): 47513–47519.
23.
ReddySTvan der VliesAJSimeoniE. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol2007; 25(10): 1159–1164.
24.
VonarbourgAPassiraniCSaulnierP. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J Biomed Mater Res A2006; 78(3): 620–628.
25.
BartlettDWDavisME. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem2007; 18(2): 456–468.
26.
Salvador-MoralesCZhangLFLangerR. Immunocompatibility properties of lipid–polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials2009; 30(12): 2231–2240.
27.
Salvador-MoralesCFlahautESimE. Complement activation and protein adsorption by carbon nanotubes. Mol Immunol2006; 43(3): 193–201.
28.
MeroASchiavonOPasutG. A biodegradable polymeric carrier based on PEG for drug delivery. J Bioact Compat Polym2009; 24(3): 220–234.
29.
HattoriRHamiltonKKMcEverRP. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem1989; 264(15): 9053–9060.
30.
SzebeniJAlvingCRMuggiaFM. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer I1998; 90(4): 300–306.
FungSYYangHChenP. Formation of colloidal suspension of hydrophobic compounds with an amphiphilic self-assembling peptide. Colloids Surf B Biointerfaces2007; 55(2): 200–211.
KisidayJJinMKurzB. Self-assembling peptide hydrogel fosters chondrocyte extracellular matrix production and cell division: implications for cartilage tissue repair. Proc Natl Acad Sci USA2002; 99(15): 9996–10001.
35.
SeminoCEMerokJRCraneGG. Functional differentiation of hepatocyte-like spheroid structures from putative liver progenitor cells in three-dimensional peptide scaffolds. Differentiation2003; 71(4–5): 262–270.
36.
HosseinkhaniHHosseinkhaniMKobayashiH. Design of tissue-engineered nanoscaffold through self-assembly of peptide amphiphile. J Bioact Compat Pol2006; 21(4): 277–296.
37.
HolmesTCde LacalleSSuX. Extensive neurite outgrowth and active synapse formation on self-assembling peptide scaffolds. Proc Natl Acad Sci U S A2000; 97(12): 6728–6733.
38.
Keyes-BaigCDuhamelJFungSY. Self-assembling peptide as a potential carrier of hydrophobic compounds. J Am Chem Soc2004; 126(24): 7522–7532.
39.
JafariMXuWNaahidiS. A new amphipathic, amino-acid-pairing (AAP) peptide as siRNA delivery carrier: physicochemical characterization and in vitro uptake. J Phys Chem B2012; 116: 13183–13191.
40.
FungSYYangHChenP. Sequence effect of self-assembling peptides on the complexation and in vitro delivery of the hydrophobic anticancer drug ellipticine. PLoS One2008; 3(4): e1956.
41.
FungSYYangHSadatmousaviP. Amino acid pairing for de novo design of self-assembling peptides and their drug delivery potential. Adv Funct Mater2011; 21(13): 2456–2464.
42.
FungSYYangHBholaPT. Self-assembling peptide as a potential carrier for hydrophobic anticancer drug ellipticine: complexation, release and in vitro delivery. Adv Funct Mater2009; 19(1): 74–83.
43.
SadatmousaviPMamoTChenP. Diethylene glycol functionalized self-assembling peptide nanofibers and their hydrophobic drug delivery potential. Acta Biomater2012; 8: 3241–3250.
44.
ZouHYWuHLZhangY. Studying the interaction of pirarubicin with DNA and determining pirarubicin in human urine samples: combining excitation–emission fluorescence matrices with second-order calibration methods. J Fluoresc2009; 19(6): 955–966.
45.
DaruwallaJNikfarjamMGreishK. In vitro and in vivo evaluation of tumor targeting styrene-maleic acid copolymer–pirarubicin micelles: survival improvement and inhibition of liver metastases. Cancer Sci2010; 101(8): 1866–1874.
46.
GreishKNagamitsuAFangJ. Copoly(styrene-maleic acid)–pirarubicin micelles: high tumor-targeting efficiency with little toxicity. Bioconjug Chem2005; 16(1): 230–236.
47.
ToneHShiraiMDanksAP. Toxicological studies on 2, R-4, 0-tetrahydropyranyl adriamycin, a new antitumor antibiotic. J Antibiot1986; 39: 327–350.
48.
TsuruoTIidaHTsukagosshI. 4′-O-tetrahydropyranyladriamycin as a potential new antitumor agent. Cancer Res1982; 42: 1462–1467.
49.
DantchevDPaintrandMHayatM. Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot1979; 32(10): 1085–1086.
50.
RaoSBSharmaCP. Use of chitosan as a biomaterial: studies on its safety and hemostatic potential. J Biomed Mater Res1997; 34(1): 21–28.
51.
LuckMPaulkeBRSchroderW. Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J Biomed Mater Res1998; 39(3): 478–485.
52.
GrefRLuckMQuellecP. “Stealth” corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces2000; 18(3–4): 301–313.
53.
PeracchiaMTHarnischSPinto-AlphandaryH. Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials1999; 20(14): 1269–1275.
54.
VittazMBazileDSpenlehauerG. Effect of PEO surface density on long-circulating PLA–PEO nanoparticles which are very low complement activators. Biomaterials1996; 17(16): 1575–1581.
55.
HamadIChristy HunterARuttKJ. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol Immunol2008; 45(14): 3797–3803.
56.
DegnSEHansenAGSteffensenR. MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation. J Immunol2009; 183(11): 7371–7378.
